


## Investigational Trials of Fedratinib in Patients with Myelofibrosis



Efficacy and Safety of Fedratinib in Patients with Primary Myelofibrosis, Post–Polycythemia Vera Myelofibrosis, or Post–Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib<sup>1,2</sup>



CONTACT: ClinicalTrialDisclosure@bms.com



Efficacy and Safety of Fedratinib vs Best Available Therapy in Patients with Primary Myelofibrosis, Post–Polycythemia Vera Myelofibrosis, or Post–Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib<sup>3,4</sup>



CONTACT: ClinicalTrialDisclosure@bms.com

The safety and efficacy of fedratinib and/or its uses are under investigation and have not been established. There is no guarantee that fedratinib will receive health authority approval or become commercially available in any country for the uses being investigated.

AE, adverse event; AML, acute myeloid leukemia; ANC, absolute neutrophil count; C6, Cycle 6; DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; G1, gastrointestinal; Int-2, intermediate-2; LCM, left costal margin; MF, myelofibrosis; MRI, magnetic resonance imaging; PB, peripheral blood; po, by mouth; PRO, patient-reported outcome; PV, polycythemia vera; QoL, quality of life; SC, subcutaneous; SVR, spleen volume reduction; US, United States; WE, Wernicke encephalopathy.

1. Clinicaltrials.gov. NCT03755518. Accessed March 18, 2021. 2. Bristol-Myers Squibb Company. Data on file (protocol number FEDR-MF-001). 3. Clinicaltrials.gov. NCT03952039. Accessed March 18, 2021. 4. Bristol-Myers Squibb Company. Data on file (protocol number FEDR-MF-002).